REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.82.

RGNX has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of REGENXBIO in a report on Wednesday, January 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. StockNews.com downgraded REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th.

Institutional Trading of REGENXBIO

Several hedge funds have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of REGENXBIO in the third quarter valued at $140,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

RGNX stock opened at $8.43 on Friday. The company has a market cap of $417.62 million, a price-to-earnings ratio of -1.68 and a beta of 1.29. The business’s 50-day moving average is $8.18 and its two-hundred day moving average is $10.13. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.